Xiaolong Tang a, b, c, f, g, 1
These authors contributed equally to this work
, Lin Liu a, b, c, 1
These authors contributed equally to this work
, Yan Li a, e, 1
These authors contributed equally to this work
, Siyu Hao a, b, c, Yueshui Zhao a, b, c, Xu Wu a, b, c, Mingxing Li a, b, c, Yu Chen a, b, c, Shuai Deng a, b, c, Shuang Gou a, b, c, Dan Cai a, b, c, Meijuan Chen a, Xiaobing Li a, Yuhong Sun a, Li Gu a, Wanping Li a, Fang Wang a, Zhuo Zhang a, Lei Yao f, g, Jing Shen a, b, c, ⁎, 2
Facsimile: 0830–-3161222
, Zhangang Xiao a, b, c, d, ⁎, 2
Facsimile: 0830–-3161222
, Fukuan Du a, b, c, ⁎, 2
Facsimile: 0830–-3161222

a Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, Sichuan 646600, China
b Cell Therapy & Cell Drugs of Luzhou Key Laboratory, Luzhou,Sichuan 646000, China
c South Sichuan Institute of Translational Medicine, Luzhou, Sichuan 646600, China
d Department of Oncology, Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan 646600, China
e Public Center of Experimental Technology, Southwest Medical University, Luzhou, Sichuan 646000, China
f The Key Laboratory for Human Disease Gene Study of Sichuan Province and Department of Laboratory Medicine, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu 610072, China
g Research Unit for Blindness Prevention of Chinese Academy of Medical Science (2019RU026), Sichuan Academy of Medical Sciences, Chengdu 610072, China